S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
An Unusual Way to Invest in Gold (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Recession risks are fading, business economists say, but political tensions pose threat to economy
Obama’s 2024 Confession (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
An Unusual Way to Invest in Gold (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Recession risks are fading, business economists say, but political tensions pose threat to economy
Obama’s 2024 Confession (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
An Unusual Way to Invest in Gold (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Recession risks are fading, business economists say, but political tensions pose threat to economy
Obama’s 2024 Confession (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
An Unusual Way to Invest in Gold (Ad)
FMC stock just set a new ceiling higher, 50% higher indeed
Recession risks are fading, business economists say, but political tensions pose threat to economy
Obama’s 2024 Confession (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

$6.74
+1.00 (+17.42%)
(As of 02/9/2024 08:56 PM ET)
Today's Range
$5.91
$6.79
50-Day Range
$4.36
$10.62
52-Week Range
$3.89
$19.32
Volume
705,200 shs
Average Volume
558,828 shs
Market Capitalization
$153.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33

Inovio Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
97.8% Upside
$13.33 Price Target
Short Interest
Healthy
98.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.37mentions of Inovio Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.80) to ($3.89) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.99 out of 5 stars

Medical Sector

213th out of 922 stocks

Surgical & Medical Instruments Industry

25th out of 92 stocks


INO stock logo

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Stock Price History

INO Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Inovio Pharmaceuticals Inc (0A43)
Obama’s 2024 Confession
Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.
Why Is Inovio Pharmaceuticals (INO) Stock Down Today?
INOVIO Plans To Submit BLA For INO-3107 In H2 - Quick Facts
Q3 2023 Inovio Pharmaceuticals Inc Earnings Call
Inovio files for $300M mixed shelf
Inovio Pharmaceuticals Inc. Q3 loss drops in line with estimates
Inovio Stock Continues To Surge: What's Going On?
See More Headlines
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2023
Today
2/12/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:INO
Employees
184
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$13.33
High Stock Price Target
$24.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+97.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-279,820,000.00
Net Margins
-19,271.31%
Pretax Margin
-19,271.31%

Debt

Sales & Book Value

Annual Sales
$10.26 million
Book Value
$10.70 per share

Miscellaneous

Free Float
22,308,000
Market Cap
$153.27 million
Optionable
Optionable
Beta
0.87

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Jacqueline E. Shea Ph.D. (Age 58)
    CEO, President & Director
    Comp: $1.08M
  • Mr. Peter D. KiesMr. Peter D. Kies (Age 61)
    Chief Financial Officer
    Comp: $688.72k
  • Dr. Laurent M. Humeau Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $673.59k
  • Thomas Hong
    Manager of Investor Relations
  • Mr. Robert L. Crotty J.D. (Age 50)
    General Counsel & Chief Compliance Officer
  • Mr. E. J. Brandreth MBA
    Senior Vice President of Quality Assurance
  • Dr. Jeffrey Skolnik
    Senior Vice President of Clinical Development
  • Mr. Robert J. Juba Jr.
    Senior Vice President of Biological Manufacturing & Clinical Supply Management
  • Mr. Stephen Kemmerrer M.B.A.
    P.E., Senior Vice President of Engineering Development
  • Mr. Shawn D. Bridy M.A.
    M.B.A., Senior Vice President of Business Development














INO Stock Analysis - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" INO shares.
View INO analyst ratings
or view top-rated stocks.

What is Inovio Pharmaceuticals' stock price target for 2024?

3 Wall Street research analysts have issued 1-year price targets for Inovio Pharmaceuticals' stock. Their INO share price targets range from $4.00 to $24.00. On average, they anticipate the company's share price to reach $13.33 in the next twelve months. This suggests a possible upside of 97.8% from the stock's current price.
View analysts price targets for INO
or view top-rated stocks among Wall Street analysts.

How have INO shares performed in 2024?

Inovio Pharmaceuticals' stock was trading at $6.12 at the beginning of 2024. Since then, INO stock has increased by 10.1% and is now trading at $6.74.
View the best growth stocks for 2024 here
.

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our INO earnings forecast
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, beating the consensus estimate of ($1.68) by $0.12. The biopharmaceutical company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 84.52% and a negative net margin of 19,271.31%. During the same period in the previous year, the business posted ($5.52) earnings per share.

When did Inovio Pharmaceuticals' stock split?

Inovio Pharmaceuticals's stock reverse split before market open on Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Green Alpha Advisors LLC (0.17%), Keystone Financial Group (0.54%), Vanguard Personalized Indexing Management LLC (0.51%), Principal Financial Group Inc. (0.30%), Simplex Trading LLC (0.00%) and Wolverine Asset Management LLC (0.00%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INO) was last updated on 2/12/2024 by MarketBeat.com Staff

My Account -